The result of the project will be the development of an innovative drug formulation, which could be used in ophthalmology. In the process of development, the concept of an innovative drug formulation will be implemented in accordance with our original methodology – Passio Innovation Way.
Many people have experienced itchiness and a gritty, dry feeling in the eyes along with increased sensitivity to pressure. The conjunctiva is red, the eyelids swollen and stuck together first thing in the morning. Draughts, the air in planes or trains, applying contact lenses and cosmetics, as well as long working hours in front of the computer all, contribute to eye pain.
During the Passio Eye Patch project, we develop an innovative drug formulation, which will solve the problem of dry eye disease (DED).
It is not easy to find out the cause of the disease and treat it accordingly. This is why only the symptoms can be treated. While quite a number of options are available for treating the condition (e.g. tear fluid substitutes), DED (dry eye disease) is still one of the greatest challenges for eye specialists. DED tends to have several causes rather than just one. Only individual symptoms can be treated and there is no ideal type of droplet for remedying all problems.
Dry eye disease (DED) is one of the most common eye diseases, affecting an estimated 300 million people worldwide. The disease mainly affects people over the age of 40, predominantly women. The condition occurs when the eyes do not produce enough tears, or when tears evaporate too quickly. As a result, the surface of the eye is no longer moist, the amount of tear fluid is reduced or has a different composition than usual. In the worst cases, the condition can lead to chronic inflammation of the cornea, damage to the surface of the cornea, potentially blurring the sight.